

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM567037

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT		
EFFECTIVE DATE:	07/10/2019		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Apotex Inc.		03/12/2020	Corporation: CANADA
RECEIVING PARTY DATA			
Name:	Intas Pharmaceuticals Limited		
Street Address:	Near Sola Bridge, S. G. Highway, Thaltej		
Internal Address:	Intas Corporate house		
City:	Ahmedabad, Gujarat		
State/Country:	INDIA		
Postal Code:	380 054		
Entity Type:	Company: INDIA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	87240794	GRAXOFIL	
Serial Number:	88260489	LAPELGA	
Registration Number:	5000903	GRASTOFIL	
CORRESPONDENCE DATA			
Fax Number:	7038164100		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	703-816-4000		
Email:	sld@nixonvan.com		
Correspondent Name:	Sheryl De Luca		
Address Line 1:	901 N. Glebe Road, 11th Floor		
Address Line 2:	Nixon & Vanderhye P.C.		
Address Line 4:	Arlington, VIRGINIA 22203		
NAME OF SUBMITTER:	Sheryl De Luca		
SIGNATURE:	/Sheryl De Luca/		
DATE SIGNED:	03/13/2020		
Total Attachments: 3			

OP \$90.00 87240794

source=Apotex assignment#page1.tif

source=Apotex assignment#page2.tif

source=Apotex assignment#page3.tif

CONFIRMATORY TRADEMARK ASSIGNMENT

This Confirmatory Assignment is made nunc pro tunc effective July 10, 2019.

WHEREAS, Apotex Inc., a corporation of Canada having its principle place of business at 150 Signet Drive, Toronto, Ontario, Canada M9L 1T9 (hereinafter "ASSIGNOR"), previously assigned all of its right, title and interest to the trademarks in the attached Schedule A, the goodwill symbolized thereby and the United States Trademark Applications and Registrations for said marks (the "Trademarks") to Intas Pharmaceuticals Limited a company of India having its principle place of business at Intas Corporate house, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad, 380 054, Gujarat, India (hereinafter "ASSIGNEE"), by and subject to the terms and conditions set forth in the Deed of Assignment of Intellectual Property Rights dated July 10, 2019 ("Deed of Assignment"); and

WHEREAS, ASSIGNOR and ASSIGNEE wish to ensure that the right, title and interest and benefit in and to ASSIGNEE to the said Trademarks can be recorded in the United States Patent & Trademark Office;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in further consideration of the mutual covenants set forth in the Deed of Assignment, ASSIGNOR confirms that it sold, assigned, transferred and conveyed by said Deed of Assignment all of its rights, title and interest in and to the Trademarks, the goodwill symbolized thereby, including the portion of ASSIGNOR's business to which the above-identified Trademarks pertain, and subject to the Deed of Assignment, does hereby sell, assign, transfer and convey, nunc pro tunc, effective July 10, 2019, to ASSIGNEE, its successors and assigns, all rights, title and interest in and to the Trademarks, the goodwill symbolized thereby, including the portion of ASSIGNOR's business

to which the above-identified Trademarks pertain, and United States applications and registrations of said marks, together with the right to sue and obtain damages, injunctive relief and/or attorney's fees by reason of any and all past infringements of the mark, or for any other violation of any other rights in or relating to said mark.

APOTEX INC.

By:  _____

Name: Kevin Zive _____

Title: VP, GIP & Legal Affairs _____

Date: March 12, 2020 _____

INTAS PHARMACEUTICALS LIMITED

By:  _____

Name: Dr. Alpesh Pathak _____

Title: Global IP Head _____

Date: 11th Mar, 2020 _____

SCHEDULE A

Registration/Application	Mark	Goods/Services
U.S. App. No. 87240794	GRAXOFIL	Biosimilar pharmaceutical preparation, namely, a granulocyte colony-stimulating factor analog used to stimulate the proliferation and differentiation of granulocytes for use with chemotherapy regimens to lessen the incidence of chemotherapy-induced neutropenia
U.S. App. No. 88260489	LAPELGA	Pharmaceutical preparations for hematopoietic growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production
U.S. Reg. No. 5000903	GRASTOFIL	Pharmaceutical preparations for [hemopoetic] *hematopoietic* growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production